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Abstract
Background: Dopamine-synthesizing (dopaminergic, DA) neurons in the ventral midbrain (VM) constitute a pivotal
neuronal population controlling motor behaviors, cognitive and affective brain functions, which generation critically
relies on the activation of Wingless-type MMTV integration site (Wnt)/b-catenin pathway in their progenitors. In
Parkinson’s disease, DA cell bodies within the substantia nigra pars compacta (SNpc) progressively degenerate, with
causes and mechanisms poorly understood. Emerging evidence suggests that Wnt signaling via Frizzled (Fzd)
receptors may play a role in different degenerative states, but little is known about Wnt signaling in the adult
midbrain. Using in vitro and in vivo model systems of DA degeneration, along with functional studies in both intact
and SN lesioned mice, we herein highlight an intrinsic Wnt1/Fzd-1/b-catenin tone critically contributing to the
survival and protection of adult midbrain DA neurons.
Results: In vitro experiments identifie Fzd-1 receptor expression at a mRNA and protein levels in dopamine
transporter (DAT) expressing neurons, and demonstrate the ability of exogenous Wnt1 to exert robust
neuroprotective effects against Caspase-3 activation, the loss of tyrosine hydroxylase-positive (TH+) neurons and
[3H] dopamine uptake induced by different DA-specific insults, including serum and growth factor deprivation, 6-
hydroxydopamine and MPTP/MPP+. Co-culture of DA neurons with midbrain astrocytes phenocopies Wnt1
neuroprotective effects, whereas RNA interference-mediated knockdown of Wnt1 in midbrain astrocytes markedly
reduces astrocyte-induced TH+ neuroprotection. Likewise, silencing b-catenin mRNA or knocking down Fzd-1
receptor expression in mesencephalic neurons counteract astrocyte-induced TH+ neuroprotection. In vivo
experiments document Fzd-1 co-localization with TH+ neurons within the intact SNpc and blockade of Fzd/b-
catenin signaling by unilateral infusion of a Fzd/b-catenin antagonist within the SN induces reactive astrocytosis and
acutely inhibits TH+ neuron survival in ipsilateral SNpc, an effect efficiently prevented by pharmacological activation
of b-catenin signaling within the SNpc.
Conclusion: These results defining a novel Wnt1/Fzd-1/b-catenin astrocyte-DA autoprotective loop provide a new
mechanistic inside into the regulation of pro-survival processes, with potentially relevant consequences for drug
design or drug action in Parkinson’s disease.
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Background
The selective loss of dopamine synthesizing (dopaminer-
gic, DA) neurons in the subtantia nigra pars compacta
(SNpc) and astrogliosis are key features of Parkinsons’di-
sease (PD), a progressive neurodegenerative disorder,
characterized by the presence of tremor, muscle rigidity,
slowness of voluntary movements and postural instabil-
ity [1]. The cause and mechanisms underlying the
demise of nigrostriatal DA neurons are not completely
clarified, but interactions between genes and environ-
mental factors are recognized to play a critical role in
modulating the vulnerability to PD [2-4]. So far, several
scenarios regarding the mechanisms by which DA neu-
rons degenerate have been suggested, including oxida-
tive stress, deficit in mitochondrial function,
excitotoxicity, accumulation of aberrant or misfolded
proteins, impairment of anti-oxidant and neuroprotec-
tive mechanisms [5-8]. In addition, current evidence
points to reactive glia as a pivotal factor in PD and
experimentally-induced rodent models, including the 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the
rotenone and the 6-hydroxydopamine (6-OHDA) mod-
els of basal ganglia injury, albeit a dual, detrimental/neu-
roprotective, influence is presently recognized [9-17].
Extensive study of these models have shown that they
mimick, in vitro and in vivo, the histhological and bio-
chemical characteristics of PD, and thus help to define
important actors critically contributing to DA cell
demise [18,19]. A body of evidences suggests that astro-
cytes play a vital role in the response of SNpc DA neu-
rons to injury or inflammation, by scavenging excess of
neurotoxic factors, removing dying cells and cellular
debris, and stimulating repair processes, while impair-
ment of astrocyte function as a result of ageing or exa-
cerbated inflammation, may critically influence
neurodegeneration and neurorepair [10-17].
The Wnt (wingless-type MMTV integration site1) path-
way has recently emerged as an essential signaling cas-
cade that regulates multiple processes in developing and
adult tissues [20-22]. In particular, substantial evidence
suggests that Wnt signaling may play a critical role in
determining the balance between neuronal survival and
death in a variety of degenerative states [23-30]. The
extracellular Wnt molecules signal into the cell via three
different pathways: the “canonical” Wnt/b-catenin and
“non-canonical” Wnt/planar cell polarity (PCP) and
Wnt (Ca2+) pathways [31]. Common to all three path-
ways is binding of the Wnt ligand to the seven-pass
transmembrane receptors of the Frizzled (Fzd) family.
The hallmark of Wnt/b-catenin pathway is the stabiliza-
tion of cytosolic b-catenin. In the absence of Wnt, b-
catenin is constantly phosphorylated by a destruction
complex consisting besides others, of glycogen synthase
kinase-3b (GSK-3b), thereby targeting it for ubiquitina-
tion and degradation by the proteasome [31,32]. Wnt
signaling inhibits GSK-3b activity, thus increasing the
amount of b-catenin, which enters the nucleus, and
associates with T-cell factor/lymphoid enhancer binding
factor (TCF/LEF) transcription factors, leading to the
transcription of Wnt target genes involved in cell survi-
val, proliferation and differentiation [31].
The Wnt/b-catenin pathway appears to play a central
role in the generation of DA neurons in the ventral
midbrain (VM) [33-37], however, little is known on
the role of Wnts and Fzd receptors in the adult intact
or PD midbrain. Using the MPTP-lesioned mouse
model which recapitulates many of the pathogenetic
processes operative in PD [19], molecular profiling of
92 mRNA species in ventral midbrain (VM) uncovered
a robust and persistent up-regulation of the canonical
Wnt agonist, Wnt1, further supported by in Situ hybri-
dization histochemistry and Western blot analysis [38].
Interestingly enough, activated VM astrocytes were
identified as candidate components of Wnt1 signaling,
and activation of Wnt1 pathway proposed as key actor
in DA recovery upon MPTP-induced nigrostriatal DA
plasticity [38].
Here, using three different in vitro models of DA toxi-
city (i.e.: serum deprivation, SD, 6-OHDA and MPP+
exposure) in purified neurons and astrocyte-neuron co-
culture paradigms, using pharmacological antagonism or
RNA silencing along with functional studies in both
intact and SN lesioned mice, we highlight an intrinsic
Wnt1/Fzd-1/b-catenin tone critically contributing to the
survival and protection of adult midbrain DA neurons




For in vitro establishment of primary mesencephalic
neuronal cultures, timed pregnant Sprague-Dawley rats
(Charles River Breeding Laboratories, Milan Italy) were
killed in accordance with Society for Neuroscience
guidelines and Italian law. For purified astrocyte cul-
tures, pups of 2-4 d of age (P2-P4) were used, as
described. For in vivo experiments, young adult (eight-
ten week-old) male C57BL/6 mice (Charles River, Calco,
Italy) housed (5 mice/cage) in a temperature (21-23°C),
humidity (60%), and light (50/50 light:dark cycle, lights
on at 06.00 a.m) controlled room, with controlled access
to food and water, were used and treated as described.
Studies were conducted in accordance with the Guide
for the Care and Use of Laboratory Animals (NIH), and
approved by the Institutional Animal Care and Use
Committee.
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Primary midbrain astroglial-neuron cultures and enriched
neuronal cultures
Primary midbrain astrocyte-neuron cultures were pre-
pared from the brain of embryonic day 13-14, as
described [39]. Briefly, mesencephalic tissues were iso-
lated and dissociated with gentle mechanical trituration.
Cells were diluted to 1.5 × 106/ml in maintenance med-
ium (MEM supplemented with 10% heat-inactivated
FBS, 10% heat-inactivated horse serum, 1 g/L glucose, 2
mM glutamine, 1 mM sodium pyruvate, 100 μM nones-
sential aminoacids, 50 U/ml penicillin and 50 μg/ml
streptomycin) and seeded into 24-well culture plates
precoated with poly-D-lysine (20 μg/ml). Plates were
maintained at 37°C in a humidified atmosphere of 5%
CO2 and 95% air. Nine-day-old cultures were used for
treatment. The composition of the cells at the time of
treatment was 54% astrocytes, 6% microglia and 40%
neurons with 1% of the neurons being TH+ neurons. To
obtain neuron enriched cultures, cytosine b-D-arabino-
furanoside (Ara-c) was added to the final concentration
of 6 μM 36 h after seeding the cells, to suppress glia
proliferation. Cultures were changed back to mainte-
nance medium 2 d later and were used for treatment 9-
12 days in vitro (DIV) after initial seeding. Neuronal
enrichment was verified by immunocytochemistry using
GFAP- and TH- and NeuN-Abs as described. Ara-c
treatment reduced glial expression by 95%. Both purified
neuronal cultures and astroglial-neuron cultures at 9
DIV, underwent serum deprivation (SD) or received
increasing doses (5, 25 or 50 μM) of the DA-specific
neurotoxins, 6-hydroxydopamine (6-OHDA), or the
active metabolite of MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPP+). For antagonism studies, we
used Dickkopf-1 (Dkk-1, R&D Systems, MN, USA 100
ng/ml). Dkk-1 is a high-affinity ligand for LRP6 and
inhibits Wnt signaling by preventing Fz-LRP6 complex
formation induced by Wnt [40]. To block the effects of
Frizzled-1 (Fzd-1) endogenous ligands, we used the
extracellular-rich domain (CRD) of Fzd-1 (recombinant
Fzd-1-CRD/Fc Chimera, R&D Systems, Minneapolis,
MN, 200-1000 ng/ml), that binds Wnt molecules with
high affinity [41-43], whereas to block Fzd-2 endogen-
ous ligands, we used the CRD of Fzd-2 receptor (recom-
binant Fzd-2 fc Chimera, R & D Systems, 200 ng-1000
ng/ml,), known to be involved in non canonical Wnt
pathway [43-45]. Conversely, exogenous activation of
Wnt/b-catenin signaling was carried out with the speci-
fic GSK-3b antagonist, AR-AO14418 [N-(4-methoxyben-
zyl)-N’-(5-nitro-1,3-thiazol-2-yl)urea] (AR, of 5 μM, 42).
Primary astrocyte cell cultures
Primary astroglial cell cultures were obtained from
mouse ventral midbrain (VM), at postnatal days 2-4
(P2-P4) as described in full details [46-48]. The cultures
were allowed to grow and differentiate until they
reached confluency at which time (13-15 days in vitro,
DIV) the loosely adherent microglial cells were sepa-
rated by shaking for 2 h at 37°C and 190 rpm. The glial
(more than 95% of the cells were GFAP-IR astrocytes)
monolayers, were rinsed with sterile PBS and replated a
final density of 0.4-0.6 × 105 cells/cm2 in poly-D-lysine
(10 μg/ml)-coated 6, 12- or 24-well plates, or in insert
membranes (0.4 μm polyethylene terephthalate) for
indirect co-culture (BD Biosciences). Astrocyte mono-
layers were processed for gene silencing and used for
indirect co-cultures with primary mesencephalic neu-
rons, as described.
Indirect astrocyte-neuron co-cultures
The specificty of astrocyte neuroprotective effect and
the contribution of Wnt1 were tested in purified neuro-
nal cultures exposed to astrocyte inserts (indirect astro-
cyte-neuron co-culture). In this experimental paradigm,
the inserts containing the astrocyte monolayer were
added on the top of the purified neurons. These inserts
allowed diffusion of factors from the glia monolayer to
the mesencephalic neurons and viceversa, without direct
contact between cells [46]. Purified mesencephalic neu-
rons grown for 9-12 DIV in maintenance medium were
shifted in medium without serum (SD-medium) and an
insert of VM astrocytes was applied on the top. For 6-
OHDA experiments, mesencephalic neurons at 9 DIV
co-cultured with VM astrocytes as described were trea-
ted with increasing concentrations (5-50 μM) of 6-
OHDA, whereas in sister cultures, Wnt1 was applied
instead of the glial monolayer. Neutralization experi-
ments were carried out with a Wnt1 antibody (ab15251-
500, lot 315275, rabbit polyclonal antibody, 2 μg/ml)
purchased from Abcam [38], as described [49,50]. The
specificity of this Wnt1-Ab was previously reported by
Cheng et al. [50] by Western blot analysis using protein
extracts from primary calvarial osteoblast and bone
mesenchymal cell cultures, and by our Western blot stu-
dies [38] using protein extracts from embryonic (E14)
ventral midbrain, the NIH/3T3 Wnt1 overexpressing
breast carcinoma cell line (Abcam), with the recombi-
nant Wnt1 protein (R & D Systems) used as a positive
control. The effect of an unrelated antibody (anti-prolac-
tin polyclonal IgG, R&D Systems) was also tested and
demonstrated to be without effect on TH+ neuron survi-
val, and served as control. The Wnt1-Ab, Dkk1, Fzd-1-
CRD or Fzd-2-CRD were added to the neuronal cultures
prior cytotoxic stimulus application. DA neuron survival
was estimated after 24 h, by counting the number of
TH+ neurons over the DAPI or NeuN-positive nuclei,
and TH+ neurons expressed as percent (%) of control
(PBS). In addition, determination of [3H]DA incorpora-
tion which reflects DAergic cell count and functionality,
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was carried out as decribed. Caspase-3 activity was eval-
uated as cell death esecutioner. In part of these neuronal
cultures protein extracts for western blot determination
of b-catenin protein levels were carried out, as
described.
Gene silencing with small interfering RNA (siRNA) and
antisense oligonucleotides treatment
To test the effect of Wnt1 or b-catenin protein deple-
tion, we used targeted mRNA degradation using siRNA
technology performed essentially as described [49-52],
and according to the protocol provided by Santa Cruz
Biotechnology. Briefly, astroglial cells were seeded at 2 ×
105/well in 6-well cluster plates (35-mm diameter wells)
in DMEM containing 10% FBS the day before lipofec-
tion. To prepare lipid-siRNA complexes, 80 pmol of the
indicate siRNA duplex in 100 μl of Transfection Med-
ium (sc-36868) and 6 μl of siRNA Transfection Reagent
(sc-29528) in 100 μl of Transfection Medium were com-
bined, incubated for 30 min at 25°C, and then diluted
with 800 μl of pre-warmed Transfection Medium. Cell
were rinsed once with serum-free DMEM, and 1000 μl
of lipid-siRNA mixture described above was applied per
well. After incubation for 6 h at 37°C in a humidified
5% CO2 cell culture chamber, an additional 1 ml of 20%
FBS in DMEM was added per well, and lipofection was
allowed to continue overnight. The next morning, the
lipofection media was aspirated, and transfected mono-
layers cells re-fed with fresh growth media (10% FBS in
DMEM). Twenty four hours later, total cellular RNA
was harvested as detailed previously using Ambion
Turbo DNase treatment and removal kit (AM1907;
Applied Biosystems) to remove all traces of genomic
DNA.
b-catenin small interference RNA (siRNA) (sc-29210)
[30,52] and control siRNA (sc-37007) were purchassed
from Santa Cruz Biotechnology. Purified mesencephalic
neurons cultured as described and plated on 24-well
plates in maintaining medium were transiently trans-
fected with siRNAs as described above. Experimental
assays were performed 72 hours post-transfection.
Phosphorothioate-modified oligonucleotides Fzd-1
antisense and sense were purchased from Metabion
International AG (Martinsried/Deutchland). Antisense
sequence was CCACCTCCTCCCGCCGGCCG, phos-
phorothioate modifications were added at both the first
and last three nucleotides, appropriate sense sequence
was used as control. The antisense oligonucleotide was
pre-incubated with 3 μl of Lipofectamine-2000 (Invitro-
gen) diluted in 100 μl of serum-free medium and then
added to the primary mesencephalic neuronal prepara-
tions at 10 DIV. Four pulses of oligonucleotide suspen-
sion was added every 6 h within a period of 24 h at a
12,5 μM final concentration, according to the protocol
described by Chacon and coworkers [51]. Control cul-
tures were treated with the same concentration of sense
oligonucleotide sequence. Treatments with 6-OHDA or
MPP+ in the absence or the presence of Wnt1 were car-
ried out simultaneously with the third pulse of oligonu-
cleotide suspension.
Quantitative RT-qPCR was carried out in triplicate
using methods described previously. Efficiency of target
mRNA knockdown (range 40-60%) was monitorized
using RT-qPCR for targeted mRNA accumulation, wes-
tern blotting and/or imunocytochemical analyses, as
described.
RNA extraction, reverse transcription and real-time PCR
RNA extraction was carried out in samples homoge-
nized in 1 ml of QIAzol Lysis Reagent (Qiagen, #79306)
using a rotor-stator homogenizer [38]. Total RNA was
isolated from homogenized samples using RNeasy Lipid
Tissue Kit (Qiagen, #74804) including Dnase digestion.
At the end, RNA samples were redissolved in 30 μl of
RNase-free water and their concentrations were deter-
mined spectrophotometrically by A260 (Nanodrop-ND
1000), and the cDNA was synthesized from 2 μg of total
RNA using the Retroscript Kit (Ambion). After purifica-
tion using QIAquick PCR Purification kit (Qiagen), 250
ng of cDNA were used for Real-time PCR using pre-
developed Taqman Assay Reagents (Applied Biosystems)
[38]. Real-time quantitative PCR was performed with
Step One Detection System (Applied Biosystems)
according to manufacturers protocol, using the TaqMan
Universal PCR master mix (# 4304437). For each sample
we designed a duplicate assay and b-actin was used
exclusively as the housekeeping gene. The assay IDs
were: Fzd-1, Mm00445405_s1; Fzd-2, Mm012504981_s1;
Fzd-3, Mm00445423_m1; Fzd-4, Mm00433382_m1; Fzd-
5, Mm03053323_s1; Fzd-6, Mm00433383_M1; Fzd-7,
Mm01255614_s1; Fzd-8, Mm00433419_s1; Fzd-9,
Mm01206511_s1; Wnt1, Mm00810320_s1; TH,
Mm00447546_m1; DAT, Mm00438388_m1; b-catenin,
Mm00483039_m1, by Applied Biosystems. We used the
housekeeping gene, b-actin, as normalizer and mouse
brain as calibrator [38]. Results are expressed as arbi-
trary units (AU).
Uptake of [3H]Dopamine
Uptake of [3H]DA was performed essentially as pre-
viously described [53], by incubating the cell cultures for
20 min at 37° with 1 μM [3H]DA in Krebs-Ringer buffer
(16 mM sodium phosphate, 119 mM NaCl, 4.7 mM
KCl, 1.8 mM CaCl2, 1.2 mM MgSO4, 1.3 mM EDTA,
and 5.6 mM glucose (PH 7.4). Non-specific DA uptake
was blocked by mazindol (10 μM). Cells were then col-
lected in 1 N NaOH after washing in ice-cold Krebs-
Ringer buffer. Radioactivity was determined by liquid
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scintillation and specific [3H]DA uptake calculated by
subtracting the mazindol counts from the wells without
the uptake inhibitor.
Caspase3 activity
After the cytotoxic insult, the cells were lysed in ice-cold
lysis buffer containing 25 mM HEPES, 5 mM EDTA, 1
mM EGTA, 5 mM MgCl2, 5 mM dithiothreitol (DTT),
1 mM phenylmethylsulfonyl fluoride (PMSF), and 10
μg/ml each of pepstatin and leupeptin, pH 7.5. The cells
were left for 20 min on ice and then sonicated. The
lysate was centrifuged for 20 min at 10 000 g and the
supernatant was quickly frozen in a methanol dry ice
bath and stored at -80°C. Lysates (30 μg protein) were
incubated at 37°C in a buffer containing 25 mM HEPES
(pH 7.5), 10% sucrose, 0.1 3-[(3-cholamido propyl)
dimethyl ammonio]-1-propanesulphonate (CHAPS), and
10 mM DTT with the fluorogenic substrate DEVD-AFC
(15 μM in dimethylsulfoxide; Calbiochem System Pro-
ducts, San Diego, CA, USA), and quantification of
DEVD-like fluorescent signal assessed in luminescence-
spectrophotometer (excitation 400 nm and emission 505
nm). Enzymatic activity is expressed as arbitrary fluores-
cent units (AFU).
Western blot analysis
Protein extracts were prepared for cell or tissue (ven-
tral midbrain which included the SNpc) samples. The
samples were homogenized in lysis buffer (0.33 M
sucrose/8 mM Hepes, pH 7.4 and protease inhibitors)
and quantified using the BCA protein determination
method (Bio-Rad, Hercules, CA). Protein samples were
diluted to equivalent volumes containing 20 μg of pro-
tein and boiled in an equal volume of Laemli SDS boil-
ing buffer (Sigma) for 10 min. Samples were loaded
into a 9-12% SDS-polyacrilamide gel and separated by
electrophoresis for 3 h at 100 V [38]. Proteins were
transferred to polyvinylidene difluoride membrane
(Amersham Biosciences, Piscataway, NJ) for 1.5 hr at
300 mA. After blocking of nonspecific binding with 5%
nonfat dry milk in TBST, the membranes were then
probed with the following primary antibodies: rabbit
anti-TH (Chemicon); rat anti-DAT (Millipore), rabbit
anti-Wnt1 (Abcam), mouse anti-b-catenin (Transduc-
tion Labs), mouse anti-GSK-3b (Transduction Labs),
mouse anti-GSK-3b phospho-Tyr216 (BD Biosciences),
goat anti-Fzd-1 (Santa Cruz Biotechnology, Inc), b-
actin (Cell Signaling). After incubation at room tem-
perature for 1 hr, membranes were washed and treated
with appropriate secondary antibodies conjugated with
horseradish peroxidase (HRP) and blot were exposed
onto radiographic film (Hyperfilm; Amersham,
Bioscience). Membranes were reprobed for b-actin
immunolabeling as an internal control [38]. The bands
from the Western blots were densitometrically quanti-
fied on X-ray films using a software to determine the
levels of immunoreactivity (ImageQuantity One). The
data from experimental bands were normalized to b-
actin. Values of GSK-3b phospho-Tyr216 were normal-
ized for its respective control, GSK-3b), before statisti-
cal analysis of variance and values expressed as per
cent (%) of saline-injected controls.
Antagonism of Wnt/b-catenin signaling by central
infusion of Dckkopf-1 (Dkk1) in the intact SNpc, in vivo
In order to link the Wnt signaling pathway to DA
cytoprotection, in vivo, we addressed the effect of
blocking Wnt/b-catenin signaling in the intact SNpc.
To this aim, we selected the specific antagonist of
canonical Wnt pathway, Dkk1 [40]. Mice were anesthe-
tized with chloral hydrate (600 mg/kg) and positioned
in a stereotaxic apparatus. The recombinant protein
Dkk1 (R&D Systems, MN, USA) was dissolved in ster-
ile physiologic saline (0.9% NaCl) at a final concentra-
tion of 1 μg/μl. Two infusions of Dkk1 were carried
out unilaterally into the SN using a 2-μl Hamilton
microsyringe and 1 μg/infusion. The following stereo-
taxic coordinates were used:3.2 posterior to bregma,
1.5 mm lateral to the midline, and 3.6 mm ventral to
the surface of the dura mater; and 3.0 posterior to
bregma, 1.3 mm lateral to the midline, and 3.8 mm
ventral [54]. The volume of the solution was infused at
a rate of 0.25 μl/min. The needle was kept in place for
5 min after each infusion before retraction. Groups of
mice received two unilateral infusion of the vehicle
(0.9% sterile NaCl, Saline) instead of Dkk1, and served
as controls. Mice were sacrificed 1, 3 and 7 days (d)
post-infusion.
Pharmacological activation of Wnt/b-catenin signaling by
preventive systemic treatment with GSK-3b antagonist, in
vivo
To address the effect of a pharmacological preventive
activation of Wnt/b-catenin signaling in Dkk1 and neu-
rotoxin-induced DA degeneration, we exogenously acti-
vated Wnt/b-catenin signaling, with the specific GSK-3b
inhibitor, AR-AO14418 (AR, [38,42,55]). AR (10 mg/kg
twice a day) was systemically (i.p.) injected starting 72 h
before Dkk1 unilateral infusion or the systemic injection
of MPTP (15 mg kg-1 free base; Sigma, dissolved in sal-
ine, 2 hours apart in one day), according to the acute
MPTP injection paradigm [19]. Groups of MPTP mice
received physiologic saline, while groups of saline-
injected mice receive AR and served as controls. Mice
were sacrificed during the peak of degeneration phase, i.
e 1-4 days post-MPTP [19], the brains were processed
for gene expression, protein determinations and histho-
pathological analyses, as described.
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Immunohistochemistry
On the day of sacrifice, mice were anesthetized and
transcardially perfused with 0.9% saline, followed by 4%
paraformaldehyde in phosphate buffer (pH 7.2 at 4°C),
the brains were carefully removed and processed as
described in full details [38,53]. Tissues were frozen and
stored at -80°C until further analyses. Serial coronal sec-
tions (14 μm-thick), encompassing the striatum (Bregma
1.54 to bregma -0.46) and the SNpc (Bregma -2.92 to
bregma -3.8 mm) according to Franklin and Paxinos
[54] were collected, mounted on poly-L-lysine-coated
slides [38,53]. The following pre-absorbed primary anti-
bodies were used: rabbit anti-tyrosine hydroxylase (TH,
Chemicon International, USA), the rate limiting enzyme
in DA synthesis; rabbit anti-TH (Peel Freez Biochem-
icals, Rogers, AR); mouse anti-TH (Boehringer Man-
nheim Bioc., Philadelphia, USA), rat anti-dopamine
transporter (DAT, Chemicon, Int. USA); rabbit anti-glial
fibrillary acidic protein (GFAP, Dako, Cytomation, Den-
mark), mouse anti-glial fibrillary acidic protein (GFAP,
Sigma, S. Luis MO, USA) as astrocyte-specific cell mar-
ker; rabbit anti-b-catenin (Abcam, Cambridge, UK) a
key intermediate in the canonical Wnt1 signaling path-
way [31]. Degenerating neurons were labelled with
Fluorojade C (FJC, Chemicon, U.S.A.) as described [56].
Nuclei were counterstained with 4’,6-diamidino-2-phe-
nylindole (DAPI) in mounting medium (Vector Labora-
tory, Burlingam, CA). Sections were washed extensively
and incubated with fluorochrome (FITC, CY3, CY5)-
conjugated species-specific secondary antibodies for
immunofluorescent detection. TH immunoreactivity was
also detected using biotinylated secondary antibodies
(Vector Laboratories) and diaminobenzidine (DAB, Vec-
tor Laboratories) as the developing agent as described
[46,47,53]. Cresyl violet was used to visualize Nissl sub-
stance. In all of these protocols, blanks were processed
as for experimental samples except that the primary
antibodies were replaced with PBS.
Cell counts and Image analysis
Quantitative analysis of DAergic neurons in the SNpc
was carried out by serial section analysis of the total
number of TH-positive (TH+) neurons throught the
entire rostro-caudal axis of the SNpc [54], as pre-
viously described [38,53]. In each section, the region of
interest, the SNpc, was outlined. Total numbers of
TH- and cresyl violet (CV)-stained neurons in adjacent
tissue sections were estimated in parallel to validate
TH+ neuron survival (TH cells/mm2). The total num-
ber of FJC-stained cells in SNpc ipsilateral and contral-
ateral to the Dkk1 or saline infusion was calculated
separately for each side, averaged for each animal and
normalized to the number of TH+ neurons in SNpc
per/side/section.
Fluorescence microscopy and image analysis were car-
ried out with a confocal laser scanning microscope
LEICA TCS-NT (Version 2.5, Build 1227, Leica Micro-
systems GmBH, Heidelberg, Germany, equiped with
image analysis software), with an argon/krypton laser
using 10 X, 20 X, and 40 × and 100 × (oil) immersion
objectives. For quantification of the amount of cells
expressing a given marker or marker combinations, the
number of TH+ cells was determined relative to the
total number of DAPI/-labeled nuclei or relative to
NeuN+ cells, using the Leica lite Software and three-
dimensional overlay to avoid false-positive/negative
overlay and double counting.
Data Analysis
Statistical significance between means ± SEM was ana-
lyzed by a two-way analysis of variance (ANOVA).
Experimental series performed on different days were
compared by the Student-Newman-Keuls t-test. A value
of p < 0.05 was considered to be statistically significant.
Results
1. Exogenous Wnt1 protects primary mesencephalic
neurons against the toxicity of SD, 6-OHDA and MPP+ via
the activation of a canonical Wnt signaling pathway, in
vitro
Our previous findings obtained in the MPTP mouse
model of PD identified spatio-temporal up- and down-
modulation of key elements of the Wnt/b-catenin sig-
naling pathway within the MPTP-injured VM associated
to DA degeneration and self-recovery [38]. In particular,
Wnt1, Fzd-1 receptor and b-catenin expression under-
went timely changes correlated to the active SNpc
degeneration phase and astroglial activation, in vivo. To
investigate the potential of Wnt1 to protect DA neurons
against cell death, via the activation of the canonical
Wnt/b-catenin pathway, we first addressed the expres-
sion of Wnt receptor, Fzd-1, and the transcriptional
activator, b-catenin, in purified mesencephalic neurons
at 9-10 days in vitro, (DIV) and next compared the
effect of exogenous Wnt1 in three well characterized in
vitro systems for the study of DA degeneration and neu-
roprotection, namely serum deprivation- (SD), 6-
OHDA- and MPP+-induced DA cell death [18,57].
A. Frizzled-1 and b-catenin are expressed in primary
mesencephalic neuronal cultures expressing the dopamine
transporter (DAT)
The first step in Wnt signal transduction is binding of
the Wnt ligand to Fzd receptors [31]. We then used real
time PCR, western blotting and immunocytochemistry,
to identify Fzd-1 receptor in purified mesencephalic
neurons at 9-10 DIV. The purity, DA nature and func-
tionality of these mesencephalic cultures was first
addressed by identifying the expression of the key
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markers of DA phenotype acquisition, tyrosine hydroxy-
lase (TH), and the dopamine transporter, DAT, both at
a mRNA (Figure 1A, B) and protein (Figure 1C, D, E,
and 1F) levels, with the adult VM serving as control tis-
sue. On the other and, the major astrocytic cell marker,
glial fibrillary acidic protein (GFAP) was not detected
(not shown). The expression of Fzd-1 was next
addressed in purified DAT-expressing cultures (Figure
1G), supporting the expression of Fzd-1 transcripts
identified in vivo in the adult VM tissue [38]. Accord-
ingly, western blotting and immunocytochemistry sup-
ported the expression of Fzd-1 at a protein level (Figure
1H, I). Dual immunofluorescent staining with TH (red)
and Fzd-1 (green) documented co-localization of the
two markers in purified neuronal DA cultures (Figure
1I). In particular, Fzd-1 immunofluorescent signal
appeared localized at the membrane level, distributed in
TH+ processes and to a lesser extent within TH+ cell
body.
We next identified b-catenin mRNA and protein levels
in DAT expressing mesencephalic neuronal cultures as
compared to the adult VM (Figure 1J, K and 1L). Immu-
nofluorescent localization of b-catenin, documented the
staining mainly at the plasma membrane. The validity of
this model was supported in parallel by application of a
DA-specific cytotxic stimulus, i.e., MPTP/MPP+, con-
firming the sharp loss of DA markers, both in vitro and
in vivo (see Figure 1A, B, C, and 1E), and by the identifi-
cation of an early (+ 24 h) and marked down-regulation
of Fzd-1 (Figure 1G, H) and b-catenin transcript and
protein levels (Figure 1J, K).
Together, these results identify in 9-10 DIV DAT-
expressing mesencephalic cultures the key elements of
the canonical Wnt signaling pathway, featuring a
marked loss of Wnt’ receptor, Fzd-1 and its transcrip-
tional activator, b-catenin, after a DA-specific insult.
B. Exogenous Wnt1 regulates TH+ neuron survival
The protective effect of Wnt ligands has been previously
observed in different cell types [26,27,51,58-60]. Given
our recent demonstration of a protective effect of Wnt1
against MPTP/MPP+, [38], the effect of a pre-treatment
with Wnt1 (100 ng/ml) before exposure to SD (12-72 h)
or 6-OHDA (5-50 μM), was then compared to MPP+
toxicity, by tyrosine hydroxylase-positive (TH+) neuron
cell counting, the incorporation of [3H] dopamine which
reflects DAergic cell count and functionality, and Cas-
pase3 activity, a key mediator of neurotoxin-induced DA
cell death. 6-OHDA and MPP+ are recognized neuro-
toxic compounds that mimick, both in vivo and in vitro,
the biochemical characteristics of PD, namely oxidative
stress and mitochondrial dysfunction (see 18, for
review). Primary mesencephalic neuronal cultures estab-
lished from E14 rat VM, when grown in PDL, in growth
medium supplemented with serum, exhibit time-
dependent increases in both the percentage of TH+ neu-
rons over the DAPI+/NeuN+ nuclei, and the incorpora-
tion of [3H]DA, incorporation. On the other hand,
withdrawal of serum resulted in the recognized time-
dependent inhibition of TH+ neuron survival (Figure
2A). Wnt1 pre-treatment, while inactive, per se, effi-
ciently counteracted SD-induced TH+ neurotoxicity, as
revealed by the significant time-dependent increase of
TH+ neurons, albeit, at later time-intervals, the protec-
tion was reduced (Figure 2A). Likewise, 6-OHDA and
MPP+ induced the known dose-dependent inhibition of
TH+ neuron survival in comparison to PBS-treated con-
trols (Figure 2B). By contrast, Wnt1 pre-treatment pro-
tected TH+ neurons in a robust concentration-
dependent manner (Figure 2B). Hence, an almost com-
plete protection was observed against 5-25 μM doses of
6-OHDA or MPP+, whereas with a 50 μM concentration
the protective effect of Wnt1 was reduced. The specifi-
city of DA neuroprotective effect of Wnt1 was further
demonstrated by its ability to counteract SD- (48 h), 6-
OHDA- (25 μM) or MPP+- (25 μM)-induced decrease
in [3H]DA incorporation as compared to cell cultures
treated with PBS (Figure 2C). Given the recognized abil-
ity of Wnts to stimulate cell proliferation in a variety of
in vitro cell systems [27,33], the potential of Wnt1 to
influence BrdU incorporation in 9 DIV mesencephalic
cultures was addressed, however only rare cells incorpo-
rated BrdU in control conditions either in the absence
or the presence of Wnt1. In the light of the critical role
of Caspase3 in the mechanisms contributing to neuro-
toxin-induced DA neuronal death death [18], the ability
of Wnt1 to alter the activity of this protease was next
assessed, using the fluorogenic substrate DEVD-AFC. As
observed (Figure 2D), DEVD-like fluorescent signal was
significantly increased 3-8 h after application of the
cytotoxic insults, implicating Caspase3 activation by this
time. In sharp contrast, Wnt1 pre-treatment efficienly
reversed up-regulation of DEVD-like fluorescent signal.
Finally, as observed in Panels E, F, G, H, I and J, and in
accord to previous reports, SD (48 h), 6-OHDA (25 μM)
and MPP+ (25 μM) induced a significant decrease in TH
+ neurite length in the surviving neurons (compare E
with F and G), whereas Wnt1 pre-treatment efficiently
reversed the decrease in neurite length (compare F and
G with H, I and J).
Together, these results indicated the ability of exogen-
ous Wnt1 to increase DA neuron capacity to survive
against SD, 6-OHDA and MPP+ as reflected by reducing
Caspase3 activation, increasing TH+ neuron number
and DA uptake and by preventing neurite degeneration.
c. b-catenin mediates the neuroprotective ability of Wnt1
The canonical Wnt signaling pathway is referred to as
Wnt/b-catenin pathway since it can regulate b-catenin
protein levels to control the activation of Wnt-
L’Episcopo et al. Molecular Neurodegeneration 2011, 6:49
http://www.molecularneurodegeneration.com/content/6/1/49
Page 7 of 29
Figure 1 Identification of Frizzled-1 and b-catenin in primary mesencephalic neuronal cultures expressing the dopamine transporter
(DAT). Enriched neuronal cultures derived from the mesencephalon of E14 rat embryos and maintained for 9-12 days in vitro (DIV) were used to
identify the dopamine transporter (DAT), Frizzled-1 (Fzd-1) and b-catenin expression as compared to adult ventral midbrain (VM), using real time
PCR, western blotting and immunocytochemistry, before and 24 h after MPTP/MPP+ insult. The values represent the means ± S.E. of three
independent experiments, each performed in triplicate. Differences were analyzed by ANOVA followed by Newman-Keuls test, and considered
significant when p < 0.05. A-B. Expression of TH (A) and DAT (B), before and after MPTP/MPP+. C-D: Western blotting of TH (C) and DAT (D) in
neurons and VM, before and after MPTP/MPP+. E-F: Representative confocal images of TH+ neuron (in red, E) and dual staining with DAT (green,
F) and TH (red), showing co-localization (orange) in SNpc neurons of the ventral midbrain.G-H: Frizzled-1 (Fzd-1) receptor mRNA (G) and protein
(H) levels in DAT-expressing neuronal cultures and VM before and after MPTP/MPP+. I:. Dual staining with Fzd-1 (in green) and TH (in red)
documenting co-localization (orange-to-yellow) of the two markers in purified neuron cultures. Note the distribution of Fzd-1 staining in TH+
processes and cell body. L-N. b-catenin mRNA (J) and protein levels (K-L) in DAT expressing neurons and VM. b-catenin+-IF signal (red, L) is
mainly in the plasma membrane, well beneath the DAPI+ nucleus. *p < 0.05 compared to -MPTP/MPP+.
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Figure 2 Wnt1 protects primary mesencephalic dopaminergic (DA) neurons against cell death induced by serum deprivation (SD), 6-
hydroxydopamine (6-OHDA) and MPP+. Enriched neuronal cultures derived from the mesencephalon of E14 rat embryos maintained for 9-12
days in vitro (DIV) were shifted to a medium without serum and growth factors (A, 12-72 h) or to increasing concentrations (5-50 μM) of 6-OHDA
or MPP+ (B) in the absence or the presence of a treatment with Wnt1 (100 ng/ml). Differences were analyzed by ANOVA followed by Newman-
Keuls test, and considered significant when p < 0.05. A-B: DA neuron survival assessed by counting TH+ neurons over the DAPI+ nuclei, and
expressed as percent (%) of PBS-treated control. C: [3H]dopamine incorporation was assessed 48 h after SD or 24 h after 6-OHDA or MPP+ (25
μM), the values expressed as % of control. D: Caspase activity was determined by measuring DEVD-AFC hydrolysis. Enzymatic determinations
were performed in lysates from cell cultures deprived of serum or challenged with 6-OHDA or MPP+ for 6 h. *p < 0.05 when compared to
control (PBS); ° p < 0.05 when compared to sister cultures exposed the cytotoxic insult (within each experimental group). E-J: Representative
images showing TH+ neurons (in red, E) and DAPI nuclear counterstaining (blue) 24 h after PBS, after 48 h of SD (F), or 24 h after 6-OHDA (G), in
absence or the presence of Wnt1 pre-treatment (H,I,J). MPP+ sharply decreases TH neurite length, an effect efficiently counteracted by Wnt1.
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responsive target genes involved in cell survival, prolif-
eration and differentiation [31,32]. Our previous in vivo
studies in the MPTP mouse model of PD documented a
dramatic and early decrease of b-catenin expression
within the VM hours after MPTP injection, thus preced-
ing and accompanying the active degenerative phase of
SNpc DA neurons [38]. We next verified the effect of
Wnt1 pre-treatment in SD, 6-OHDA and MPP+ induced
changes in b-catenin mRNA and protein levels. As
shown in Figure 3A, while SD (48 h), 6-OHDA (25 μM),
or MPP+ (25 μM) exposures resulted in a dramatic
decrease of b-catenin transcript (A) and protein (B), the
preventive application of Wnt1, while inactive, per se,
efficiently reversed b-catenin downregulation, both at a
mRNA and protein levels.
To further address the involvement of b-catenin as a
pro-survival factor for mesencephalic TH+ neurons, we
depleted b-catenin protein in enriched neuronal cultures
via the introduction of b-catenin siRNA [30,52]. Real
time PCR (A) and western blotting (B) showed that b-
catenin siRNA introduction caused an almost 40-60%
decrease in b-catenin levels as compared to a control
siRNA. In b-catenin siRNA pre-treated cultures, the
number of TH+ neurons was significantly reduced as
compared to neuronal cultures treated with control
siRNA, supporting the critical role of b-catenin for TH+
neuron survival. Moreover, the toxic effect of SD, 6-
OHDA or MPP+ were further amplified in neuronal cul-
tures deprived of b-catenin, as reflected by a further
signicant decrease of TH+ neuron survival and the
incorporation of [3H] dopamine as compared to neuro-
nal cultures exposed to the different neurotoxic insults
but pre-treated with control siRNA (Figure 3C, D).
These findings are in line with previous studies in differ-
ent cell systems, and further underlined the crucial
importance of b-catenin transcription for DA neuron
survival. In these experimental conditions, the ability of
Wnt1 to protect TH+ neurons against 6-OHDA or MPP
+ insult, was significantly reduced, as revealed by
reduced TH+ neuron numbers (Figure 3C) and neurite
length (compare panels 3F, G and H, and 3J, K and L)
and decreased [3H] dopamine incorporation (Figure 3D),
as opposed to neuronal cultures treated with control
siRNA, where Wnt1 treatment afforded TH+ neuropro-
tection (Figure 3C, D and 3F, G, H and 3J, K, L).
Together, these informations indicate b-catenin down-
regulation as a key contributor of neurotoxin-induced
TH neuron death. In addition, the ability of Wnt1 to
increase TH neuron survival requires b-catenin tran-
scriptional activity.
D. Frizzled-1 receptor is required for Wnt1-induced TH
neuroprotection
Taking into consideration the broad expression pattern
of Fzd receptors, their developmental regulation and
differential expression in various tissues including the
developing midbrain [33], we asked whether besides
Fzd-1, other Fzd components are expressed in our DAT
+ cultures at 10 DIV, and explored the effect of neuro-
toxic challenge. Using real time PCR and specific Fzd
primers (Figure 4A), we found that DA neurons harbor
most Fzd receptors, albeit Fzd-1 was almost 2-4- fold
more abundant as compared to Fzd-2, Fzd-3, Fz-6 and
Fzd-8 transcripts, while other Fzds were expressed at a
lower level. In addition, as reported in the case of MPP+
toxic challenge (Figure 1G, H), DA neuron exposure to
either SD or 6-OHDA significantly down-regulated Fzd-
1 but not Fzd-2 or Fzd-6, while a slight reduction was
observed for Fzd-3, but no diference for Fzd-8 and Fzd-
9 mRNAs (Figure 4A), indicating differential modulation
of Fzd transcript levels under the studied cytotoxic con-
ditions. The marked down-regulation of Fzd-1 mRNA
was further supported at a protein level, as assessed by
Western blot analysis (Figure 4B) and immunofluores-
cent staining (Figure 4C, D, E, F, G, H). Hence, SD, 6-
OH-DA or MPP+ challenge significantly reduced Fzd-1
protein, an effect efficiently counteracted by preventive
application of Wnt1 (Figure 4B, G, H). Dual staining
with TH (in red) and Fzd-1 (in green) further supported
MPP+- and 6-OHDA-induced Fzd-1 downregulation,
whereas Wnt1 prevented neurite loss and Fzd-1 receptor
down-regulation, thereby supporting Wnt1 protective
effect (compare panels 4E, F with G, H). In the light of
the different Fzd components found, and to verify the
specific contribution of Fzd-1 in Wnt1 neuroprotective
effect, we thought to assess the effect of Fzd-1 antisense
oligonucleotides (Fzd-1AS). We first assessed the ability
of Fzd-1AS to induce a reduction of Fzd-1 at a protein
level, as opposed to treatment with the sense oligonu-
cleotide (Fzd-1Ct) (Figure 4B). This effect was specific
for Fzd-1 since Fzd-1AS did not changed the expression
of Fzd-2 (AU: 0.38 ± 0.05 vs 0.33 ± 0.06, in Fzd-1Ct and
Fzd-1AS, respectively). The protective effect of Wnt1
was then evaluated in Fzd-1Ct - and Fzd-1AS -treated
neuronal cultures (Figure 4I, J, K, L). In PBS-treated or
injured cultures, Fzd-1AS did not significantly modified
TH+ neuron numbers or DA uptake levels (Figure 4I, J).
However, in Wnt1 treated cultures, the pre-treatment
with Fzd-1AS efficiently counteracted Wnt1-induced TH
+ neuroprotection against the different cytotoxic insults,
as revealed by the failure to counteract the decreased
TH+ neuron numbers and [3H]DA incorporation (Figure
4I, J). Likewise, in Fzd-1AS-treated neuronal cultures,
Wnt1 failed to reverse the loss of b-catenin (Figure 4K)
as it did in control neuronal cultures treated with the
sense control. Of special interest, treatment with Fzd-
1AS inhibited the ability of Wnt1 to reverse TH+ neurite
degeneration upon cytotoxic challenge, as compared to
cultures treated with Fzd-1Ct (Figure 4M, N, O and 4P).
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Figure 3 b-catenin depletion abolishes Wnt1-induced TH+ neuroprotection. Enriched neuronal cultures were transiently transfected with b-
catenin small interference RNA (b-cateninsiRNA) (sc-29210) or control siRNA (b-cateninCt, see text for details), before being exposed to either Wnt1
or PBS, and DA neuron survival assessed by counting TH+ neurons, by assessing [3H]dopamine incorporation and Caspase3 activity. Differences
analyzed by ANOVA followed by Newman-Keuls test, and considered significant when p < 0.05. A-B: Effect of SD, 6-OHDA and MPP+ treatments
in b-catenin mRNA (A) and protein levels (B) showing a significant decrease of b-catenin. Note that preventive application of Wnt1 increases b-
catenin both at a mRNA (A) and protein levels (B). *p < 0.05 vs PBS. Depletion of b-catenin via the introduction of b-catenin siRNA shows an
almost 40-60% reduction in b-catenin mRNA by Real time PCR (A) and western blotting (B). *p < 0.05 vs control siRNA C-D: Survival of TH+
neurons by cell counting (C), [3H]dopamine incorporation (D). Note that in b-catenin siRNA pre-treated cultures, the application of Wnt1 failed to
protect TH+ neurons against 6-OHDA or MPP+, whereas in cultures pre-treated with a control siRNA, Wnt1 treatment increased TH+ neuron
survival (C) and [3H]dopamine incorporation (D). E-L: Representative immunocytochemical images show the ability of Wnt1 to efficiently
counteracts TH neuron death and neurite loss, an effect abolished by b-catenin silencing *p < 0.05 vs cultures without cytotoxic insult; ** p <
0.05 compared to siRNACt+ cytotoxic insult (within each each experimental group); ° p < 0.05 compared to Wnt1 treated cultures in the
presence of siRNACt.
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Figure 4 Knocking down Fzd-1 counteracts Wnt1-induced TH+ neuroprotection. Enriched neuronal cultures were processed for Real time
PCR using specific primers for Fzd receptors. The effect of knocking down Fzd-1 in Wnt1 neuroprotection was studied with Fzd-1 sense (Fzd-
1Ct) or antisense (Fzd-1AS) oligonucleotides. Differences were analyzed by ANOVA followed by Newman-Keuls test, and considered significant
when p < 0.05. A: Differential expression and regulation of Fzd transcripts by SD, 6-OHDA and MPP+. B: Western blot (wb) analysis showing
down-regulation of Fzd-1 levels in neuronal cultures exposed to the cytotoxic stimuli and the significant reversal induced by Wnt1. *p < 0.05 vs
cultures without cytotoxic insult. Pre-treatment with Fzd-1AS induced an almost 40-60% decrease of Fzd-1. C-H: Representative confocal images
of dual staining with Fzd-1 (green) and TH (red) showing colocalization (orange to yellow) in PBS (C-D) controls. Note the marked loss of Fzd-1 in
TH neurons exposed to 6-OHDA (E) or MPP+ (F), an effect efficiently counteracted by Wnt1 pre-treatment (G). I-J: Survival of TH+ neurons by cell
counting (C), [3H]dopamine incorporation (D). K-L: Effect of Fzd-1 AS or Fzd-1Ct, in b-catenin protein and Caspase3-like activity. Fzd-1AS pre-
treatment prevents Wnt1-induced increased b-catenin protein levels (K) and reverses Wnt1-induced Caspase3-inhibition (L) in 6-OHDA and MPP
+-treated cultures. *p < 0.05 vs PBS. *p < 0.05 vs control siRNA. Note that Wnt1 efficiently reversed the dramatic decrease of neurite length
caused by 6-OHDA or MPP+ in Fzd-1Ct-treated (M, N), as opposed to Fzd-1 knocked down cultures (O, P). *p < 0.05 vs cultures without insult
(within each each experimental group).
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In keeping with these findings, in Fzd-1AS pre-treated
cultures, Wnt1 failed to reverse the increase of Caspase3
activation, as it did in Fzd-1Ct cultures (Figure 4L),
thereby establishing that Fzd-1 is required to transduce
exogenous Wnt1 signal into TH+ neurons, to stabilize b-
catenin and to inhibit apoptosis via blockade of Cas-
pase3 activation.
E. Active GSK-3b is efficiently antagonized by Wnt1
Given the pivotal role played by GSK-3b in Wnt/b-cate-
nin pahway and its emerging implication in oxidative-
stress-induced neuronal cell death mechanisms, includ-
ing 6-OHDA, rotenone and MPTP/MPP+ [61-67], the
effect of Wnt1 in the response of active GSK-3b (evi-
denced by increased tyrosine phosphorylation at residue
216, p-Tyr216-GSK-3b), was next addressed in parallel
with the determination of Caspase3 activation (Figure
5). Importantly, our previous spatio-temporal analysis in
the VM of MPTP-treated mice, in vivo, showed up-reg-
ulation of active GSK-3b preceeding and accompanying
the active degeneration phase within the SNpc [38]. In
analogy with previous findings, neurotrophic factor
deprivation, 6-OHDA or MPP+ [62-66] significantly
increased activated GSK-3b (i.e. p-Tyr216-GSK-3b) (Fig-
ure 5A-B). On the other hand, Wnt1 pretreatment sig-
nificantly reduced p-Tyr216-GSK-3b up-regulation
induced by SD, 6OHDA or MPP+ (Figure 5A, B). The
ability of Wnt1 to decrease p-Tyr216-GSK-3b was also
compared to the effect of specific GSK-3b inhibitor, AR
AO-14418 (AR, 5 μM). Hence, pre-treatment of neuro-
nal cultures with AR efficiently reversed the up-regula-
tion of p-Tyr216-GSK-3b (Figure 5A, B). When the
survival of TH+ neurons was studied, AR, while inactive,
per se, increased TH+ neuron numbers in response to
either SD, 6-OHDA or MPP+ (Figure 5C). In addition,
the concomitant treatment with Wnt1 and AR afforded
a full protection, as compared to either treatment alone.
Consistently, DEVD-like immunofluorescent signal was
sharply decreased in neuronal cultures treated with AR
or Wnt1, and further inhibited by the combined treat-
ments. On the other hand, the specific antagonism of
canonical Wnt pathway with Dkk1 efficiently reversed
Wnt1-induced TH+ neuroprotection and Caspase3-like
activity inhibition (Figure 5C, D), supporting Wnt1 acti-
vation of a canonical Wnt/b-catenin signaling pathway
associated to inhibition of the pro-apoptotic GSK-3b
pathway [61-67].
2. Ventral midbrain (VM) astrocytes mimick Wnt1-induced
TH neuroprotection: contribution of endogenous Wnt1
and Fzd-1/b-catenin signaling pathway
Astrocytes represent a vital source of survival and neu-
rotrophic factors for several types of neurons, including
DA neurons [10,16,17,35,38,46,57,68,69]. In particular,
astrocytes are equipped with a robust anti-oxidant
system and are known to protect neurons from oxida-
tive stress and growth factor deprivation-induced cell
death [1,10,17,48,57,69-72]. This function appears of
paramount importance for DA neurons, known to be
particularly vulnerable to oxidative damage. Given our
recent identification of VM astrocytes as putative source
of Wnt1 expression in the MPTP-injured VM [38], we
next addressed in this second part of this work, the
putative role of astroglial Wnt1 in TH+ neuroprotection
in the described experimental conditions. Using the
direct co-culture paradigm, exposing the mesenecephalic
cultures to SD as above, or addition of 6-OHDA, or
MPP+, resulted in a remarkable protection of TH+ neu-
ron numbers and [3H]DA incorporation (Figure 6A, B)
as opposed to purified neurons cultured alone (see Fig-
ure 2). In addition, TH+ neurites appeared significantly
protected by contact with astrocyte and astrocyte-
derived factors, as revealed by increased neurite length
and branching (compare Figure 2F and 2G with Figure
6E, F, G and 6J), thereby supporting the recognized neu-
rotrophic and neuroprotective effects of mesencephalic
astrocytes. However, when exposure to the SD, 6-
OHDA or MPP+ was associated with the application of
Dkk1, a sharp counteraction of astrocyte-mediated TH+
neuron protection was observed (Figure 6A-B and 5H,
K). Conversely, the exogenous activation of Wnt/b-cate-
nin signaling with the specific GSK-3b inhibitor AR-
14418 (AR, 5 μM), resulted in a significant potentiation
of astrocyte-induced increase in TH+ neuron survival
and [3H]DA incorporation (Figure 6A,B, I, L, M). Inter-
estingly, dual staining with TH (N, red) and Fzd-1 (O,
green) revealed a significant increase in Fzd-1 immuno-
fluorescent signal, at the cell body and along the
branched neurites and at the growth cones of the res-
cued TH+ neurons (Figure 6Pand inset). The contribu-
tion of Wnt1 to glial neuroprotective effects was next
studied using a Wnt1-Ab. The specificity of this Wnt1-
Ab was previously reported by Cheng et al. [50] by
Western blot analysis using protein extracts from pri-
mary calvarial osteoblast and bone mesenchymal cell
cultures, and by our Western blot studies [38] using
protein extracts from embryonic (E14) ventral midbrain,
the NIH/3T3 Wnt1 overexpressing breast carcinoma
cell line, using the recombinant Wnt1 protein as a posi-
tive control (Figure 6D). Hence, application of this
Wnt1-Ab in the co-culture system significantly reduced
both TH+ neuron survival and [3H]DA incorporation
(Figure 6A, B), as opposed to the application of an unre-
lated antibody (anti-prolactin polyclonal IgG, not
shown), which was without effects. In order to study the
effect of Wnt1-Ab and Dkk1 on Wnt/b-catenin signal-
ing, we used the indirect astrocyte-neuron co-culture
paradigm. In this experimental condition, the glial
inserts were added on the top of the purified neurons at
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9 DIV. As observed in Figure 6C, western blot analysis
indicated that astrocyte-derived factors efficiently
reversed the marked down-regulation of b-catenin pro-
tein levels observed in neurons cultured alone and
exposed to the different cytotoxic insults (compare Fig-
ure 3B with Figure 6C). By contrast, neuronal b-catenin
protein levels were significantly reduced when DA
neurons were preventively exposed to either Wnt1-Ab
or Dkk1 (Figure 6C), supporting Wnt/b-catenin signal-
ing activation in astrocyte-mediated neuroprotection
against the studied cytotoxic insults.
Given that different endogenous astrocyte-derived
Wnt ligands may activate Fzd receptors in DA neurons,
we decided to block the effects of Fzd-1 endogenous
Figure 5 Effect of Wnt1-induced TH+ neuroprotection on active GSK-3b and Caspase3-like activity. Purified neuronal cultures were
exposed to SD, 6-OHDA or MPP+ insults as described, and DA neuroprotection examined as above. Active GSK-3b (GSK-3b phospho-Tyr216)
protein levels were determined by western blotting (wb). Part of the cultures were pre-treated with Wnt1 (100 ng/ml) or the the specific GSK-3b
antagonist, AR-14418 (5 μM), alone or in combination, while other cell cultures were exposed to the specific antagonist of Wnt/b-catenin
pathway, Dkk1 (100 ng/ml), 1 hr before Wnt1 (100 ng/ml) treatment. Differences were analyzed by ANOVA followed by Newman-Keuls test, and
considered significant when p < 0.05. A-B: Active GSK-3b (GSK-3b phospho-Tyr216) protein levels as determined by wb. A sharp up-regulation is
observed after SD, 6-OHDA or MPP+ insults, an effect reversed by Wnt1 and AR pre-treatment. B: Survival of TH+ neurons exposed to the
described insults in the absence or the presence of the different treatments. * p < 0.05 when compared to control cultures without cytotoxic
insults. Note that both Wnt1 and AR increase TH+ neuron survival, and the combined Wnt1+AR treatment further increase TH+ neuron survival.
By contrast, exposure of Dkk1-pretreated cultures to SD, 6-OHDA or MPP+ reduced Wnt1 protective effect on cell survival. C: Caspase-3 activity
shows a sharp inhibition of DEVD-like activity in neurons pre-treated with Wnt1 or AR and exposed to the different insults, whereas previous
exposure to Dkk1, counteracts Wnt1-induced Casapse3 inhibition. * p < 0.05 when compared to control cultures without cytotoxic insults.
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Figure 6 Modulation of astroglial Wnt1/b-catenin signaling directs towards TH neuron survival/death. Astrocyte-neuron co-cultures
where shifted to serum deprived medium (SD, A), or received 6-OHDA or MPP+ (25 μM), with or without Dkk1 (100 ng/ml), a Wnt1-Ab, or AR-
14418 (5 μM) as described. A-B: TH+ neuron counts (A), and [3H]dopamine uptake (B) 48 h after SD or 24 h after 6-OHDA or MPP+(25 μM) with
or without Dkk1, Wnt1-Ab, or AR. * p < 0.05 compared to controls. C: Western blot analysis showing b-catenin levels in neurons exposed to
astrocyte insert upon cytotoxic challenge with or without Wnt1-Ab or Dkk1. In this experimental condition, the glial inserts were added on the
top of the purified neurons at 9 DIV. D: immunoblotting with Wnt1-Ab (50) using protein extracts from embryonic VM and the NIH/3T3 cell line.
50 ng of recombinant Wnt1 was used as a positive control. E: Dual staining with TH (red) and DAPI depicting TH+ neurons in a control (PBS)
astrocyte-neuron co-culture. D-P: Confocal images showing dual staining with TH (green) and GFAP (red) in a typical astrocyte-neuron control
co-culture at 9 DIV. Note the lenght and branching of TH+ processes. Astrocyte coculture induced a significant protection against SD (E), 6-
OHDA (H), and the reversal induced by Dkk1 antagonism of Wnt/b-catenin signaling (F,I). By contrast, pharmacological activation of Wnt/b-
catenin signaling with AR magnified TH neuroprotection (G,J,K). Astrocyte coculture increases Fzd-1 signal in the long and branched TH+ neurites
and growth cones (L-N and insert).
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ligands using the CRD of Fzd-1 (Fzd-1-CRD, 1 μg/ml)
involved in canonical signaling [41-43], or Fzd-2 endo-
genous ligands, using the CRD of Fzd-2 receptor (1 μg/
ml,), known to be involved in non canonical Wnt path-
way [43-45]. As observed (Figure 7A, B), indirect co-cul-
ture efficiently mitigated SD, 6-OHDA- and MPP
+-induced neurotoxicity, as revealed by the significant
increase in TH+ neuron survival and [3H] DA uptake, as
well as by the efficient counteraction of Caspase3 activa-
tion (Figure 7C). By contrast, when the neuronal cul-
tures were treated with Fzd-1-CRD and then exposed to
the different neurotoxic insults, Astro-induced DA neu-
roprotection was significantly mitigated, as revealed by
the failure to increase TH+ neuron survival and DA
uptake (Figure 7A, B), or to decrease Caspase3-like
activity (Figure 7C). Interestingly enough, exposure of
purified neuron in co-culture with astrocytes to Fzd-1-
CRD, caused a small decrease in TH+ neuron survival,
indicating that astrocyte-derived Fzd-1 ligands (includ-
ing Wnt1), may modulate mesencephalic neuron survi-
val in basal conditions. By contrast, treatment of DA
neurons with the soluble CRD of Fzd-2 receptor, did
not significantly affected astrocyte-induced neuroprotec-
tion against SD, 6-OHDA and MPP+, as revealed by TH
+ neuronal cell counts, DA uptake levels, and Caspase3-
like activity, implying that in these experimental condi-
tions, Fzd-1 but not Fzd-2 endogenous ligands are
involved in TH neuroprotection. Together, these infor-
mations supported the participation of Wnt1 and Fzd-1
ligands as opposed to Fzd-2 endogenous ligands in
astrocyte neuroprotective effects.
A. Silencing Wnt1 in VM astrocytes fails to protect TH+
neurons
To further dissect the role of a paracrine canonical
Wnt1 tone and link astrocyte-derived Wnt1 via Fzd-1
and b-catenin to DA neuroprotection, we next examined
the effects of depleting Wnt1 in VM astrocytes by intro-
ducing a small interference RNA targeting Wnt1, Astro
siWnt1 [46]. In analogy to our previous in vivo and ex
vivo findings [38], showing increased Wnt1 transcript
levels in VM astrocytes upon MPTP injury, both SD
and 6-OHDA induced a significant increase in Wnt1
mRNA (Figure 7D), whereas, in DA neurons, Wnt1
transcript levels were almost 20-40- fold lower (AU:
0,02 ± 0,01) in both basal conditions or after exposure
to cytotoxic insults, likely suggesting a paracrine Wnt1
modulatory control. In Astro siWnt1, RT-qPCR analysis
demonstrated reduced targeted cognate mRNA accumu-
lation by 40-60% by 72 h. Accordingly, immunocyto-
chemical analyses confirmed depletion of Wnt1 protein
(Figure 7E, F). The glial inserts transiently transfected
with siRNAwnt1 or siRNAcontrol were then added on the
top of the purified neurons at 9 DIV. As observed in
Figure 7G, exposure of purified neuron co-cultured with
Astro siWnt1 resulted in significant albeit, small decrease
in TH+ neuron survival, reminiscent of the small
decrease observed after Fzd-1-CRD, and supporting that
astrocyte-derived Wnt1 represents an endogenous survi-
val stimulus for mesencephalic neurons. In addition, in
neurons co-cultured with Astro siWnt1, SD or 6-OHDA
sharply reduced TH+ neuronal count, [3H]DA incor-
poration, and neurite length, as compared to neuron co-
cultured with AstrosiControl (Figure 7Gand Panels I-S). In
addition, in co-culture with Astro siWnt1 the cytotoxic
insults resulted in a significant increase in DEVD-like
caspase activity, as compared to neurons co-cultured
with Astro control, where DEVD-like fluorescent signal
was similar to control cultures (Figure 7H), underscor-
ing astrocyte-derived Wnt1 as a vital survival factor for
DA neurons.
The specific involvement of a Wnt/Fzd1/b-catenin sig-
naling cascade in astrocyte-mediated DA neuroprotec-
tion was further illustrated in neuronal cultures pre-
treated with b-catenin siRNA or Fzd-1AS. Hence, silen-
cing b-catenin or knocking down Fzd-1 in DA neurons
mimicked the effect of silencing Wnt1 in astrocytes. As
observed in Figure 7G, in DA neurons treated with b-
catenin siRNA or Fzd-1AS, astrocyte inserts failed to
exert neuroprotection, as reflected by the the significant
decrease in the number of TH+ neurons (Figure 7G),
thereby supporting among others, the critical role of
Wnt1, b-catenin and Fzd-1 for astrocyte promotion of
TH+ neuron survival.
All together, these findings clearly indicated the ability
of endogenous astrocyte-derived Wnt1 to afford a signif-
icant degree of protection of mesencephalic DA neurons
against SD, 6-OHDA and MPP+ cytotoxicity via a cano-
nical Fzd-1/b-catenin signaling pathway.
3. Effect of modulation of Wnt/b-catenin signaling in vivo
in intact and injured SNpc
To address the physiological relevance of this pathway
in the maintenance/protection of midbrain DA neurons
in vivo, the effect of inhibition of Wnt/b-catenin signal-
ing in intact neurons, or activating this pathway in
acutely lesioned SN neurons was next investigated.
A. Acute interruption of Wnt signaling by intracerebral
infusion of Dkk1 within the intact SNpc decreases TH+
neuron survival
The effect of a specific antagonist for canonical Wnt sig-
naling was next assessed using Dkk1 [40]. To this end,
Dkk1 (1 μg/μl) or physiologic saline, was unilaterally
infused into the left intact SNpc, as described. Groups
of mice received unilateral infusions of saline and served
as controls. Mice were sacrificed at different time-inter-
vals post-infusion, and the brains processed for stereolo-
gical determinations of TH+ neuron survival. As
observed in Figure 8A, B and 8C, unilateral infusion of
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Figure 7 Antagonizing Wnt signaling or Silencing Wnt1 in VM astrocytes fail to protect TH+ neurons. Wnt antagonism studies were
performed with the extracellular-rich domain (CRD) of Fzd-1 (Fzd-1-CRD, 1 μ/ml) and the CRD of Fzd-2 (Fzd-2-CRD,1 μ/ml). Depletion of Wnt1 in
VM astrocytes was achieved by introducing a small interference RNA targeting Wnt1, Astro siWnt1 (46) in indirect astrocyte-neuron co-cultures (42).
A-C: Indirect astrocyte-neuron co-culture efficiently mitigated SD, 6-OHDA- and MPP+-induced decreased TH neuron survival (A), DA uptake (B),
and Caspase3 activation (C), whereas these protective effects are reversed by Fzd-1-CRD pre-treatment, but not Fzd-2-CRD. * p < 0.05 when
compared to control cultures without cytotoxic insults; ° p < 0.05 compared to neurotoxic exposure within each experimental group. D-F: Glial
inserts transiently transfected with siRNAwnt1 or siRNAcontrol were added on the top of the purified neurons at 9 DIV and exposed to cytotoxic
stimuli. RT-qPCR analysis (D) and immunocytochemistry (E-F) show an almost 40-60% Wnt1 depletion by 72 h. G-H: In neurons co-cultured with
Astro siWnt1, irrespective of the cytotoxic stimulus, a sharp reduction of TH+ neuronal count (G) and increased Caspase3-like activity (H) were
observed, compared to neuron co-cultured with AstroCt (p < 0.05). In b-catenin siRNA- and Fzd-1AS-knocked down neurons, astrocyte inserts
failed to promote neuroprotection. I-S : Confocal images of TH staining (green) in the indirect cocultures showing the protective effect of
astrocyte inserts + siRNACt (L,O,R) as compared with siRNAWnt1 (M,P,S). The effect of indirect astrocyte coculture is emphasized in the PBS control
cultures (I, N).
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Figure 8 Effect of intracerebral infusion of a Fzd receptor antagonist within the intact SNpc in the number of TH+ Nissl+ and
Fluorojade-C (FJC) cell bodies. The effect of blocking Wnt/b-catenin signaling was assessed using the negative modulator of Wnt1 signaling,
Dkk1 (1 μg/μl) or saline, unilaterally infused into the left intact SNpc, as described. Mice were sacrificed 1-7 days post-infusion, and the brains
processed for TH+ Nissl+ cell counts (M) and Fluorojade C staining (FJC, N) in consecutive midbrain sections. A-L: Confocal images showing TH+
(green) neurons counterstained with DAPI (blu) of coronal midbrain sections at the level of the SNpc 1 day after unilateral saline (A-C) or 1 (D-F),
3 (G-I) and 7 (J-L) days after unilateral Dkk1 infusion. In Dkk1-infused mice, a decrease of TH+ immunofluorescent signal was observed starting 1
d (D) in the ipsilateral (E), but not contralateral (F), non-infused SN, with a peak TH+ loss at 3 days (see H compared to I), and a stabilization
observed by 7 days (F). M. Total number of TH+ and Nissl+ counted throught the entire rostro-caudal axis of the SNpc. Treatment groups were
averaged (n = 4/time-point, means ± S.E.M.) * p < 0.05 vs contralateral side, within each respective group. B. Total number of Fluorojade C (FJC)
stained cells in SNpc ipsilateral and contralateral to the infusion was calculated for each side, averaged for each animal (n = 4/time-point) and
normalized to the number of TH+ neurons in SNpc per section. *p < 0.05 vs saline injected side.
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saline did not cause any significant differences in the
number of TH+ (revealed by FITC, in green) neurons
ipsilateral (B) to the infusion, as compared to the con-
tralateral (C) SNpc. By contrast, in Dkk1-infused mice
(Figure 8D, G and 8J), an acute decrease of TH+ neu-
rons was observed in the ipsilateral (E,H,K), compared
to the contralateral (F,I,L), non-infused SN. Estimation
of the total number of TH+ Nissl+ neurons confirmed a
reduction in Dkk1-infused ipsilateral as compared to
contralateral saline-injected SN 1 -7 d post-treatment,
with a maximal decrease in TH+ Nissl+ neuron survival
measured by 3 d (Figure 8M). By 7 d, a modest return
TH neurons was observed, indicating that a certain
mumber of TH neurons had survived the Dkk1 insult
(Figure 8M). The degeneration of SNpc neurons was
next monitored with Fluorojade C (FJC, 56). As
observed, a time-dependent increase in the percentage
of FJC-stained cells was selectively observed within the
SNpc, at 1-3 d post-Dkk1, whereas by 7 d post-Dkk1,
only rare FJC-stained cells could be counted (Figure
8N), corroborating the reciprocal loss of TH+ Nissl+
cells. Together, these findings supported an actual acute
TH+ neuron loss instead of a loss of TH expression
after Dkk1 infusion in the intact SNpc, suggesting that
inhibition of Wnt/b-catenin signaling may represent a
potential causative factor for DA neuron death.
B. Effect of interruption of Wnt/b-catenin signaling in Fzd-1
receptors and b-catenin expression in TH+
We next conducted spatio-temporal analyses in order to
correlate Fzd-1 receptor (Figure 9A, B) and b-catenin
(Figure 9C, D) by immunohistochemical and western
blotting (Figure 9E-G). Dual staining with Fzd-1 (red)
and TH (green), supported the in vitro results, revealing
the colocalization of both markers in saline-infused con-
tralateral SN (Figure 9A). Accordingly, Fzd-1 receptor
showed, a distribution in TH+ processes and was also
localized in TH+ cell bodies. Dual staining with DAT
and b-catenin revealed colocalization, of both markers,
with b-catenin staining mainly in the plasma membrane
and TH+ cell bodies, localized abundantly beneath the
cell nucleus (Figure 9C). By contrast, Dkk1 infusion lead
to a dramatic down-regulation of both Fzd-1 (Figure 9B,
E, G) and b-catenin (Figure 9D, F, G) within the tem-
poral window of the degeneration phase (Figure 8M, N),
with an initial, albeit small return observed by 7 d.
Together, these findings indicated that acute inhibition
of Fzd-1 and b-catenin proteins after infusion of Dkk1
in the intact SN affected the integrity of TH+ neurons
leading a significant inhibition of TH+ neuron survival.
Moreover, Fzd-1 receptor and b-catenin down-regula-
tion correlated, within the temporal window of FJC-
staining in SNpc degenerating neurons (Figure 8N),
pointing to Wnt/b-catenin signaling as an endogenous
pathway linked to the maintenance of adult midbrain
DA neurons, while its inhibition appeared associated to
TH+ neurodegneration in SNpc.
C. Astrocyte response to acute interruption of Fzd/b-catenin
signaling
As a next step we verified the response of VM astro-
cytes to Dkk1 infusion (Figure 10A-J). Both immunohis-
tochemistry (A, D, G) and Western blotting (J) showed
a sharp and sustained increase of GFAP protein levels
within the VM ipsilateral to the lesion, starting already
by 1 d post-infusion and remaining significantly higher
throught the experimental period, as compared to GFAP
protein levels measured in unilaterally infused SN with
saline, or in contralateral uninfused SN. Dual staining
with GFAP (in red) and TH (in green) supported a
marked increase in GFAP+ astrocytes within the ipsilat-
eral Dkk1-infused SN, 1-7 d post-infusion (compare
panels A, B, C with D, E, F and G, H,I). Hypertrophic
GFAP+ astrocytes were abundant within the ipsilateral
SN of Dkk1- infused (D,G), as compared to contralateral
(E,H) uninfused SN, or saline-infused (panels A-B) SN,
thereby indicating a time- and site-specific GFAP
response to Dkk1 intranigral infusion, likely reflecting a
potential compensatory response of reactive astrocyte to
the acute interruption of Fzd/b-catenin signaling.
D. Effect of pharmacological activation of Wnt/b-catenin
signaling in TH+ neuroprotection against Dkk1 or MPTP
neurotoxicity
To address a potential therapeutical relevance of this
pathway, we next thought to mimick the activation of
Wnt1/b-catenin signaling by selecting the pharmacologi-
cal inhibition of GSK-3b enzyme activity since it results
in the activation of b-catenin signaling. Moreover, our
recent results indicated a dysfunctional Wnt1/b-catenin
cascade in the VM of middle-aged mice that do not
recover from MPTP insult, and showed the ability of
pharmacological activation of b-catenin [38], post-injury
(i.e. 3 d post-MPTP) to promote neurorepair in ageing
mice. Together these findings coupled to the present
results enabled us to examine the functional importance
of this pathway in protecting DA neuron degeneration
against Dkk1 and MPTP insult. To this end, the specific
GSK-3b inhibitor, AR, was injected i.p. (10 mg/kg twice
a day) starting 72 h before unilateral Dkk1 infusion
within the SN, or 72 h before the systemic (i.p.) treat-
ment with the parkinsonian neurotoxin, MPTP, accord-
ing to the subacute injection paradigm (15 mg kg-1, 4
times a day at 2 h intervals), and mice were sacrificed
after the active degeneration phase (4 days post-MPTP).
As observed in Figure 11, preventive systemic treatment
with AR successfully prevented the significant loss of
TH+Nissl+ cells induced by either Dkk1 or MPTP (Fig-
ure 11A, B, C and 11D). Of special importance Wnt/b-
catenin pathway activation successfully prevented
MPTP-induced loss of TH+Nissl+ neurons (D). Hence,
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Figure 9 Effect of intracerebral infusion of a Fzd receptor antagonist in Fzd-1 and b-catenin expression within the SNpc. Spatio-
temporal analyses of Fzd-1 (A-B) receptors and b-catenin (C-D) protein levels by western blot (A-B) and immunohistochemical (C-F) analyses
within the SN ipsilateral and contralateral to saline or Dkk1 infusion. A-B: Representative images showing dual staining with Fzd-1 (red) and TH
(green) in the SNpc of saline (C) and Dkk1- (D) infused SN, 3 days post-infusion. Colocalization (C, orange to yellow and Mag) of the two markers
reveals Fzd-1 receptor expression in TH+ neurons. Note Fzd-1 receptor punctate distribution in TH+ processes and bright signal also in DA cell
bodies, occasionally Fzd-1-IF signal was observed in TH- neurons, but not in GFAP+ astrocytes (not shown). Dkk1 infusion induces loss Fzd-1
receptor in ipsilateral SNpc (B). C-D: Dual staining with DAT (E, green) and b-catenin (red) revealed colocalization, of both markers, with b-catenin
staining mainly in plasma membrane and TH+ cell bodies, abundantly beneath the cell nucleus (C and Mag), whereas in SN ipsilateral to Dkk1
infusion, b-catenin signal was down-regulated (D). E-G: Fzd-1 and b-catenin protein within the ipsi- and contra SN of saline and Dkk1-infused
mice (n = 4/time-point) by western blot, showing downregulation of Fzd-1 and b-catenin in Dkk1-ipsi but not contralateral SN. Data from the
experimental bands were normalized to b-actin, and values expressed as per cent (%) of saline-injected controls. *p < 0.05 ipsilateral vs
contralateral, within each respective group; ° p < 0.01 compared to ipsi-lesioned side.
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dual immunofluorescent staining with TH and GFAP
showed the recognized loss of TH neurons 4 d post-
MPTP associated with the known increase of GFAP
+astrocyte density [10,38,53], as compared to saline
injected mice (Figure 11A, B), and the remarkable pro-
tective effect exerted by AR systemic injections starting
72 h before MPTP (Figure 11 C, D). This AR-induced
DA neuroprotection was not due to a difference in stria-
tal MPTP/MPP+ metabolism, since no significant
changes were observed in striatal MPP+ levels between
MPTP/AR and MPTP/saline mice [38].
Together, these in vivo findings suggest that interrup-
tion of Wnt/b-catenin signaling may represent a causa-
tive factor leading to DA neuron death, whereas
activation of Wnt/b-catenin signaling in SNpc can pre-
vent TH+ neuron degeneration in the MPTP mouse
model of PD.
Discussion
The present study uncovers a canonical Wnt1 paracrine
tone as an endogenous signal required for DA neuron
maintenance and protection. First, we demonstrated the
expression of Fzd-1 receptors in mesencephalic DAT
expressing neurons in primary culture and determined
that b-catenin is a downstream effector of Wnt1 signal-
ing pathway that mediates neuroprotection against SD,
6-OHDA neurotoxicity, and MPP+, in vitro. Second, by
using specific antagonist for canonical Wnt pathway,
siRNA to deplete b-catenin, or antisense oligonucleo-
tides to knock down Fzd-1, we showed the failure of
Wnt1 ligand to efficiently protect TH+ neurons against
SD or 6-OHDA-induced cytotoxicity, identifying a cano-
nical Wnt1/Fzd-1/b-catenin signaling as a novel poten-
tial neuroprotective pathway. Third, we characterized
astroglial-derived Wnt1, via Fzd-1/b-catenin signaling, as
Figure 10 Effect of intracerebral infusion of a Fzd receptor antagonist in GFAP response within the SNpc. The response of glial fibrillary
acidic protein (GFAP) was assessed by immunohistochemical (A-I) and western blot (L)analyses within the SN ipsilateral and contralateral to
saline or Dkk1 infusion. A-I: Representative immunofluorescent images of dual staining with GFAP+ (red) and TH (green) in SN ipsilateral and
contralateral to saline or Dkk1 infusion. In saline-infused SN, there was no significant difference between the ipsilateral (A) and contralateral (B)
SN, whereas Dkk1 infusion induced a marked increase in astrocyte density within the ipsilateral Dkk1-infused SN, at 1 (not shown), 3 (C) and 7 (E)
days post-infusion, compared to contralateral (compare with D, F). Note the increased density of hypertrophic GFAP+ astrocytes abundantly
covering the ipsilateral SN of Dkk1- infused (see F and I), as compared to saline-infused SN (C), thereby indicating a time- and site-specific GFAP
response to Dkk1 intranigral infusion. J: GFAP protein levels within the ipsi- and contralateral SN of saline and Dkk1-infused mice (n = 4/time-
point) by western blot (wb), showing a marked up-regulation of GFAP in Dkk1-ipsi but not contralateral SN by 1 day post-infusion, and further
increasing at 3 and 7 days post-Dkk1. By contrast, unilateral saline infusion within the right SN was without effect on GFAP protein levels. Data
from the experimental bands were normalized to beta-actin, and values expressed as per cent (%) of intact uninjected controls. *p < 0.05
ipsilateral vs contralateral, within each respective group.
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Figure 11 Effect of pharmacological activation of Wnt/b-catenin signaling in TH+ neuroprotection against intracerebral Dkk1 or
systemic MPTP treatment. To mimick the activation of Wnt1/b-catenin signaling, we selected the specific GSK-3b inhibitor, AR (10 mg/kg twice
a day) starting 72 h before unilateral Dkk1 infusion within the SN, or before the systemic (i.p.) treatment with the parkinsonian neurotoxin, MPTP
(15 mg kg-1, 4 times a day at 2 h intervals), and mice sacrificed at the peak degeneration phase (3 days post-treatment). A-B: Representative
confocal images showing dual localization of TH+ neurons (green) and GFAP+ astrocytes (red) in Saline (A), MPTP (B) and AR/MPTP (C) 4d post-
MPTP, showing the sharp decrease of TH neurons associated to the marked astrocytosis and the remarkable protective effect of AR (C). C: The
total number of TH+ and Nissl+ neurons was counted throught the entire rostro-caudal axis of the SNpc as above. Treatment groups were
averaged (n = 4/time-point, means ± S.E.M.) * p < 0.05 vs unifused side (for Dkk1), within each respective group. Dkk1 and MPTP significantly
reduced TH+ and Nissl+ neurons 4 d post-treatment. MPTP systemic treatment reduces TH+ neuron numbers in both left and both sides. Note
the remarkable counteraction afforded by AR in increasing TH+ neurons to unlesioned saline-treated control. *p < 0.05 vs -MPTP.
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one chief component of DA neuroprotective loop, since
knocking down Wnt1 in midbrain astrocytes abolished
DA neuroprotection, a condition mimicked by b-catenin
silencing or Fzd-1 knock down in DA neurons. Conver-
sely, activation of Wnt/b-catenin signaling in purified
neuronal cultures with a specific GSK-3b antagonist,
efficiently reversed TH neuron demise. Consistently,
unilateral infusion of the specific antagonist of canonical
Wnt pathway, Dkk1, within the intact SN, in vivo, down-
regulated b-catenin and Fzd-1 and promoted TH+ neu-
ron degeneration and astrocyte reaction ipsilateral to
Dkk1, but not in contralateral uninfused SN. Finally, the
preventive pharmacological activation of Wnt/Fzd/b-
catenin signaling efficiently counteracted Dkk1- or
MPTP-induced TH+ neuron demise in vivo, defining
Wnt1/Fzd-1/b-catenin pathway as a novel astrocyte-neu-
ron signaling system required for survival and protection
of adult midbrain DA neurons (Figure 12). All together,
these data provide compelling evidence that ongoing
canonical Wnt-Fzd-b-catenin signaling is required for
the survival of adult midbrain neurons. Coupled to the
observed dysregulation of Wnt/b-catenin signaling in
the midbrain of aged mice that fail to recover upon
MPTP insult [38], these observations suggest the possi-
bility that neuronal loss in PD could arise from dysfunc-
tional Wnt/Fzd/b-catenin signaling, with potential
implications for our understanding of the pathogenesis
and therapy of Parkinson’s disease.
Fzd-1 receptor via b-catenin signaling is a candidate
downstream pro-survival effector for mesencephalic DA
neurons
Wnt proteins comprise a family of 19 cysteine-rich gly-
cosylated proteins that function through a canonical
pathway targeting b-catenin or through non-canonical
b-catenin independent pathways. Fzd receptors have an
extracellular amino-terminal region that contains a
cysteine-rich domain (CRD) consisting of 120 to 125
residues with 10 conserved cysteines that is necessary
for the binding of Wnt molecules [41]. The Fzd-depen-
dent signaling cascade comprises several branches,
whose differential activation depends on specific Wnt
ligands, Fzd receptor isoforms and the cellular context
[44,45,73], which increases the complexity of the Wnt
signaling cascade. In the mature nervous system, the
roles of Wnts and Fzds are not clarified, but a potential
role for Wnt pathway as a pro-survival signaling cascade
in a variety of degenerative disease states has recently
emerged [23-30,51,58-60,74,75]. While little is known
about the receptors that mediate Wnts effects in the
adult brain, in the hippocampus, Fzd-1 represent a
potential target, since it is expressed at high levels
[51,76,77] and mediate the neuroprotective effect of
Wnt3a against Ab toxicity [51]. In addition, the synaptic
localization of Fzd-1 receptor in mammalian neurons
was recently shown for the first time, and suggested to
mediate the synaptic effects of the Wnt signaling path-
way [43]. Here, we report that mature midbrain DAT-
expressing neurons harbor most Fzds, among which the
canonical Wnt’s receptor, Fzd-1, is the most abundant.
Accordingly, Fzd-1, together with its key transcriptional
activator, b-catenin, were shown to colocalize with TH+
neurons within the SNpc, thereby supporting the bind-
ing and action of a potential endogenous Wnt ligand in
adult midbrain DA neurons. Interestingly enough, neu-
rotoxic challenge is accompanied by a sharp down-regu-
lation of Fzd-1 receptors in TH+ neurons at a mRNA
and protein levels, both in vitro and in vivo, whereas
other Fzds were not affected, suggesting a link between
Fzd-1 downregulation and DA neuron vulnerability to
cytotoxic insults. We next addressed the ability of exo-
genous Wnt1 to afford TH neuroprotection against dif-
ferent cytotoxic insults including SD, 6-OHDA or MPP
+, via the activation of canonical Wnt signaling. In DA
neurons, withdrawal of serum and neurotrophic factors
exacerbate oxidative stress, thus constituting a recog-
nized cytotoxic stimulus. Likewise, 6-OHDA and MPP+
are widely used tool for the study of neuroprotective
drugs in PD models, both in vivo and in vitro (see 18).
Neuronal cell death caused by neurotoxin-induced oxi-
dative stress, lead to the opening of the mitochondrial
permeability transition pore (mPTP), resulting in the
release of cytochrome C and the activation of caspases
[18,19]. We thus linked temporal increases of b-catenin
at a mRNA and protein levels with the timing of Cas-
pase3 inhibition, and the resulting increase in TH+ neu-
ron survival and [3H]dopamine incorporation, upon
Wnt1 treatment. The specificity of this result was next
supported by different lines of evidences. In a first case,
we explored the direct role of b-catenin in mediating
the prosurvival effects of Wnt1, using siRNA to knock
down b-catenin protein in enriched neuronal cultures,
and showed a strict b-catenin-dependency for TH+ neu-
ron survival both in basal conditions, and under neuro-
toxic challenge. In particular, decreased TH+ neuron
survival was potentiated in b-catenin silenced cultures
exposed to the diffent neurotoxic stimuli. Moreover,
Wnt1 failed to efficiently counteract TH+ neuron
demise, while increasing Caspase3-like activity. In addi-
tion, antagonism of Wnt canonical signaling with Dkk1,
significantly reduced Wnt1-promoted increase in b-cate-
nin protein and TH+ neuron survival. Given the differ-
ent Fzd receptor components identified in our DA
neuronal cultures, it appeared important to verify the
specific contribution of Fzd-1 in Wnt1 neuroprotective
effect. Interestingly, we observed that Wnt1 reversal of
SD, 6-OHDA or MPP+ toxicity promoted a significant
Fzd-1 receptor up-regulation both at a mRNA and
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Figure 12 Schematic illustration of Wnt1/Fzd-1/b-catenin signaling as a candidate regulatory circuit controlling mesencephalic
dopaminergic neuron-astrocyte crosstalk. Crosstalk between astrocytes and DA neurons represent a cardinal neuroprotective mechanism
against inflammation, oxidative stress and growth factor deprivation (10). Here astrocyte-DA neuron crosstalk via Wnt1 is emphasized. Astrocyte-
derived Wnt, via activation of Fzd-1 receptors, may contribute to maintain the integrity of DA neurons by influencing Wnt signaling components,
including blockade of GSK-3b-induced phosphorylation (P) and proteosomal degradation of the neuronal pool of b-catenin. Stabilized b-catenin
can translocate into the nucleus and associate with a family of transcription factors and regulate the expression of Wnt target genes involved in
DA neuron survival. b-catenin may also function as a pivotal defense molecule against oxidative stress (79), and can act as a coactivator for
several nuclear receptors involved in the maintenance/protection of DA neurons (81). Crosstalk with up-stream survival pathways converging to
b-catenin stabilization can also be envisaged (26, 27). Neurotoxic injury or increased oxidative load as a result of aging may antagonize Wnt/b-
catenin signaling in DA neurons by up-regulating active GSK-3b, leading to b-catenin degradation and increased DA neuron vulnerability, which
may underlie a progressive DA neuron deficit. Neuronal injury also triggers reactive astrocyte expression of a panel of growth and neurotrophic
factors, anti-oxidant and neuroprotective mechanisms, among which astrocyte Wnt1 via Fzd-1 receptors may function as a vital component of
DA neurons self-protective machinery shifting the balance towards the programming of cell survival/neurorescue.
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protein levels, associated to a remarkable increase of TH
+ neurite length. In sharp contrast, antisense oligonu-
cleotide knock down of Fzd-1 in DA neurons resulted
in a significant counteraction of TH+ neuroprotection
both at a biochemical and morphological levels, asso-
ciated to a marked loss of b-catenin protein and
increased Caspase3 activation, as opposed to neuronal
cultures treated with the sense control, clearly establish-
ing that Fzd-1 is required to transduce the Wnt1 signal
into TH+ neurons, to stabilize b-catenin and to inhibit
apoptosis via blockade of Caspase3 activation. These
results are in line with a body of evidences, indicating
the protective abilities of exogenous Wnts against a vari-
ety of cytotoxic insults including SD-, Ab- or TNFa-
induced apoptosis through b-catenin-dependent or inde-
pendent mechanisms, whereas the presence of Wnt’s
antagonists has been generally linked to the occurrence
of apoptosis [23-30,51,58-60]. In the absence of Wnt
activity, GSK-3b is known to phosphorylate b-catenin at
serine or threonine residues of the N terminal region to
predispose degradation of b-catenin through ubiquina-
tion [27]. The fact that Wnt1 pre-treatment efficiently
reversed SD-, 6-OHDA- and MPP+-induced GSK-3b
activation (i.e. increase in pSer216) coupled to the the
reversal of neurotoxin-induced TH+ neuron demise by
the specific GSK-3b inhibitor AR, further documented
the participation Wnt1/Fzd/b-catenin signaling cascade
in DA neuron death/survival. Because the Wnt pathway
also uses protein kinase B (Akt) to promote cell survival,
and since Akt inhibits the activity of GSK-3b through
phosphorylation of this protein to promote cell survival
[26,27,64,67], the participation of Akt in the observed
effects is likely to occur and deserves further investiga-
tions. Together, these results indicate the ability of
Wnt1 via Fzd-1 to activate b-catenin, also via the inacti-
vation of GSK-3b thereby blocking the phosphorylation
of b-catenin, followed by transcription of its target
genes for cellular protection, pointing to Wnt1/Fzd-/b-
catenin transcriptional activation as a critical down-
stream pro-survival effector for mesencephalic DA neu-
rons. Importantly enough, stabilizing neuronal b-catenin
was recently shown to render neurons “anti-apoptotic”
in cell cultures and transgenice mice models [30] and
recent in vivo studies have emphasized that down regu-
lation of Wnt/b-catenin signaling results in hippocampal
neurodegeneration [78].
Crosstalk signaling pathways in astrocyte-DA neuron
dialogue are triggered upon cytotoxic insults: a paracrine
protective role for astroglial born Wnt1
Midbrain DA neurons are exquisitely sensitive to oxida-
tive stress and growth factor withdrawal and significant
changes indicative of mitochondrial dysfunction, oxida-
tive stress and inflammation, proteasomal deficits and
apoptosis have been identified in the human parkinso-
nian brain (for reviews, see 1,2,5,8). Astroglial-derived
growth and neurotrophic factors are recognized to pro-
tect neurons from a variety of pro-apoptotic stimuli,
including SD, 6-OHDA or MPP+ [4,10-17,57,68-72].
Given the indication that Wnt components are
expressed in adult astrocytes [22,79], and that Wnt1
transcription is induced in VM astrocytes upon MPTP
injury [38], we thus reasoned that astroglial Wnt1
expression might represent a more general compensa-
tory self-protective signal, and herein addressed whether
the cytotoxic cascade induced by the different neuro-
toxic insults might trigger the activation of a common
self-defensive pathway in astrocyte-neuron co-cultures,
in vitro, that might converge to the stabilization of b-
catenin in DA neurons (Figure 12). Indeed, b-catenin
functions as a pivotal molecule in defense against oxida-
tive stress [80], and can also act as a coactivator for sev-
eral nuclear receptors involved TH neurons
development, maintenance and neuroprotection [81,82].
Thus, activation of Wnt1/b-catenin appeared one attrac-
tive pathway that might work in concert with astrocyte-
derived factors to maintain the integrity and protect TH
+ neurons. Using the specific antagonist for canonical
Wnt pathway, Dkk1, we showed a significant reversal of
astrocyte-induced TH+ neuroprotection, an effect
accompanied by inhibition of b-catenin protein levels in
DA neurons, supporting the participation of Wnt/b-
catenin signaling. Given that different Wnts may contri-
bute to astrocyte-induced neuroprotection observed in
this study, we thought to antagonize the effect of endo-
genous Wnt molecules that bind with high affinity to
Fzd-1 receptor, using the CRD of Fzd-1 [41-43]. In addi-
tion, we tested the effect of blocking Wnt molecules
that bind with high affinity to Fzd-2, shown to activate
non-canonical Wnt pathways [43-45], using the CRD of
Fzd-2 receptor. The fact that only Fzd-1-CRD sharply
counteracted astrocyte-induced neuroprotection, thus
supported that activation of endogenous Fzd-1-mediated
signaling contributed to astrocyte neuroprotective
effects. While additional in depth analyses are required
to unravel the contribution of other endogenous Wnt
ligands/Wnt pathway components, the critical role of
Fzd-1 ligands and b-catenin transcriptional activation in
astrocyte-induced neuroprotection was further evi-
denced by the demonstration of a lack of neuroprotec-
tive effects of astrocyte inserts when either b-catenin or
Fzd-1 were knocked down.
That Wnt1 might represent the critical Wnt molecule
was next corroborated by different lines of evidences.
Firstly, by the demonstration of the lack of effects upon
TH+ neuroprotection induced by VM astrocytes in the
presence of a specific Wnt1-Ab. Secondly, depleting
Wnt1 in VM astrocytes by introducing a small
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interference RNA targeting Wnt1, which resulted in a
significant decrease of TH+ neuron survival upon SD, 6-
OHDA or MPP+ treatments, as compared to neurons
co-cultured with Astro Ct. Inhibition of TH+ neuron
survival was associated to a marked loss of b-catenin
protein levels, and activation of Caspase3 in purified
neurons. In addition, activation of Wnt/b-catenin signal-
ing with a specific GSK-3b antagonist, significantly
potentiated the astrocyte ability to protect TH neurons.
The fact that in basal conditions, depleting or neutraliz-
ing astroglial Wnt1, or antagonizing Fzd-1 endogenous
ligands, had a small inhibitory effects on TH+ neuron
survival, imply a positive feedback mechanism in which
astroglial Wnt1 signaling is required to maintain TH+
neuron integrity, whereas defects in Wnt/Fzd signaling
could cause of neuronal loss. Within this context, and
of particular interest, co-culture with VM astrocytes
markedly increased Fzd-1 immunofluorescent signal
within the rescued TH+ neurons, at the neurites and
growth cones, as opposed to the dramatic down-regula-
tion of Fzd-1 receptor observed in purified neurons,
either in vitro or in vivo after the neurotoxic insult.
Coupled to the information showing Wnt1-induced up-
regulation of Fzd-1 receptors in purified DA neurons
upon cytotoxic challenge (Figure 4B), these findings
further suggest that Wnt1 signaling may contribute to
maintain the expression of Wnt signaling components
in DA neurons, corroborating the presence of a para-
crine astrocyte-neuron autoregulatory loop. In addition,
given the potential role of Fzd receptors localized at
growth cones in regenerating neurites [83], the critical
role of Fzd-1 receptor recently characterized in presy-
naptic differentiation and function of hippocampal neu-
rons [43], further studies are clearly needed to clarify
the role of Fzd-1 ligands and Fzd-1 receptors localized
at the growth cones in TH+ neurons, for neurite out-
growth, maintenance and regeneration in conjunction
with astroglial-derived factors. Together, the presented
in vitro results indicated astroglial born Wnt1 via Fzd-1/
b-catenin signaling activation as a chief component of
DA neurons self-protective machinery and highlight a
candidate regulatory autoprotective circuit controlling
midbrain DA neuron-astrocyte crosstalk via astroglial
Wnt1 (Figure 12).
A paracrine Wnt tone contributes to maintain TH+ neuron
integrity in the intact adult midbrain
Mis-regulation of Wnt/b-catenin signaling has been
involved in the pathology of Azheimer’s disease (AD)
[23-30,51,60]. While at an early stage, Wnt cascades
have recently been linked to Parkinson’s disease. Hence,
downregulation of b-catenin in DA neurons of the SN
[84] and up-regulation of active GSK-3b in striatum
[66] have been reported in PD. Consistently, genetic
screens revealed GSK-3b polymorphisms with altered
transcription and splicing in PD [85]. Other studies have
revealed mutations in Wnt/b-catenin signaling activated
transcription factor, Nurr1 [86], the orphan nuclear
receptor involved in DA neurodevelopment and neuro-
protection [82]. Gene expression profiling in progres-
sively MPTP-lesioned macaques indicated down-
regulation of b-catenin and dysregulation of key compo-
nents of Wnt signaling [87]. Of special interest, muta-
tions in PARK8, encoding leucine-reach repeat kinase
(LRRK2), which represent a major cause for PD [88],
were recently linked to Wnt signaling [89] via interac-
tion with the key components, Dishevelled [90] and
GSK-3b. On the other hand, Parkin, the product of the
PARK2 gene, has been reported to inhibit Wnt signaling
[91], whereas a-Synuclein, a presynaptic protein causal
in PD, contributes to GSK-3b-catalyzed Tau (a protein
linked to tauopathies, such as AD) phosphorylation
(pTau) in PD disease models [66]. Hence, in the last
part of these studies we addressed the physiological rele-
vance of Fzd-1/b-catenin pathway in the maintenance of
adult midbrain DA neurons by investigating the effect of
Dkk1 infusion in the intact SNpc. Our previous studies
documented Fzd-1 receptor expression in the adult VM
by real time PCR and western blot analysis, however it
was not clear which cell type (neurons or glia) might
harbor Fzd-1 receptor. Here, we uncovered that Fzd-1
receptors and b-catenin colocalize with TH+ and DAT+
but not in GFAP+ cells (not shown). In earlier studies,
intracerebral infusion of Dkk1, or inactivating lentiviral
vectors expressing Wnt inhibitor/stimulator were used
as tools to investigate the potential role of the canonical
Wnt pathway [22,92,93]. Here, unilateral infusion of
Dkk1 caused a time-dependent decrease of TH+ neuron
numbers in the ipsilateral infused, but not in contralat-
eral uninfused SN, whereas unilateral infusion of saline
within the SN, did not change TH+ neuron number in
either ipsilateral or contralateral SNpc. That the Dkk1-
induced loss of TH+ neurons was due to Wnt/b-catenin
antagonism, and not to a non-specific effect, was further
demonstrated by at least two other lines of evidence:
first, an early and sharp down-regulation of Fzd-1 recep-
tor and b-catenin proteins was revealed in the ipsilateral
as opposed to the contralateral SN; second, such b-cate-
nin down-regulation preceded and accompanied the
tempo of TH+ neuron degeneration, revealed by FJC
staining, in the face of a marked up-regulation of active
GSK-b, wich disclosed, in vivo, a critical role for a para-
crine canonical Wnt/b-catenin tone as an endogenous
pathway linked to the survival/maintenance of adult
midbrain DA neurons. This acute decrease in cell num-
ber, showed an initial return by 7 d post-Dkk1, likely
suggesting the possible activation of repair mechanisms
within the SN microenvironment. Interestingly enough,
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a marked increase of reactive astrocytes within the ipsi-
lateral Dkk1-infused SN was observed, with hyper-
trophic GFAP+ cells abundantly covering the ipsilateral
SN, as compared to saline-infused SN, and longer time-
course studies, actually in progress, are clearly needed to
further analyze both astrocyte and TH+ neuron response
with time. The present study does not answer the ques-
tion about the specific endogenous ligand/mechanism(s)
involved, and further in depth analyses, will help clarify-
ing this issue. The fact that the preventive activation of
b-catenin signaling by pharmacologic inhibition of active
GSK-3b, efficiently promoted TH+ neuron protection in
either Dkk1- or MPTP-lesioned SN, clearly implicate a
causative link between the interruption of Wnt signaling
and the acute degeneratione of SNpc TH+ neurons.
In conclusion, activation of Wnt/Fzd-1/b-catenin path-
way appears determinant for the maintenance of a nor-
mal complement of TH+ neurons in the adult SNpc.
Fascinatingly, Wnt1-induced neuroprotection is closely
integrated with the astroglial response to oxidative stress
and inflammation upon injury, and requires Fzd-1
receptor and b-catenin stabilization to convey pro-survi-
val signals to the nucleus, whose expression likely
underlie the observed neuroprotection. Thus, up-stream
and down-stream modulation of astroglial Wnt1/Fzd-1/
b-catenin pathway may tip the balance between apopto-
sis and the programming of cell survival/neurorescue in
these models (Figure 12). An in-depth understanding in
the molecular pathways and their crosstalk underlying
midbrain neuroprotection will be crucial to identify new
avenues for pharmacological and cell replacement thera-
pies against Parkinson’s disease.
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